| Stereochemistry | ABSOLUTE |
| Molecular Formula | C45H55F2N6O8S2.Na |
| Molecular Weight | 933.07 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].COC1=CC=C2C(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@@H](CC(=O)N5CCCC(F)(F)C5)CCCCCC=C[C@@H]6C[C@]6(NC4=O)C(=O)[N-]S(=O)(=O)C7CC7)=CC(=NC2=C1C)C8=NC(=CS8)C(C)C
InChI
InChIKey=KLBYIWFUEHNOSA-ACPQSSBHSA-M
InChI=1S/C45H56F2N6O8S2.Na/c1-26(2)34-24-62-41(49-34)33-21-37(32-15-16-36(60-4)27(3)39(32)48-33)61-30-20-35-40(55)50-45(43(57)51-63(58,59)31-13-14-31)22-29(45)12-9-7-5-6-8-11-28(42(56)53(35)23-30)19-38(54)52-18-10-17-44(46,47)25-52;/h9,12,15-16,21,24,26,28-31,35H,5-8,10-11,13-14,17-20,22-23,25H2,1-4H3,(H2,50,51,55,57);/q;+1/p-1/b12-9-;/t28-,29-,30-,35+,45-;/m1./s1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C45H56F2N6O8S2 |
| Molecular Weight | 911.088 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Deldeprevir (Neceprevir) is a direct-acting anti-HCV drug developed by Achillion. Deldeprevir acts by inhibition of the viral NS3/4A protease. In phase 1b clinical trial for the treatment of chronic HCV infection, the drug was safe and well-tolerated and produced more than a 3 log10 mean maximum reduction in plasma HCV RNA levels in all treated groups. Despite positive results, no development of the drug was reported by Achillion since 2014.
